Biocon Biologics and Civica Expand Partnership to Broaden U.S. Diabetes Treatment Options

Biocon Biologics Ltd., a fully integrated global biosimilars company, and Civica, Inc., a non-profit generic pharmaceutical company, have expanded their strategic collaboration to include a new Insulin Glargine medicine. This partnership aims to increase the supply of high-quality affordable insulins in the U.S. Biocon Biologics will manufacture and supply the medicine to Civica, who will commercialize it under their own label and trade dress. The agreement creates an exclusive distributorship arrangement and does not involve any technology transfer. Biocon Biologics will continue to directly commercialize its own Insulin Glargine-yfgn medicine in the U.S. The partnership will help to reach underserved populations through new channels, aligning with Biocon Biologics' mission to expand access to affordable, high-quality insulins.